{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:17:02Z","timestamp":1795209422210,"version":"4.10.3"},"reference-count":80,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.waojou.2026.101474","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:55:31Z","timestamp":1790110531000},"page":"101474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies"],"prefix":"10.1016","volume":"19","author":[{"given":"Aleena","family":"Banerji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cancian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Guilarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Radojicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avner","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.waojou.2026.101474_bib1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaip.2023.12.025","article-title":"Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema","volume":"12","author":"Riedl","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101474_bib2","first-page":"s292","article-title":"Severity of hereditary angioedema, prevalence, and diagnostic considerations","volume":"24","author":"Bernstein","year":"2018","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.waojou.2026.101474_bib3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","article-title":"Hereditary angioedema: diagnosis, clinical implications, and pathophysiology","volume":"40","author":"Sinnathamby","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.waojou.2026.101474_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.anai.2025.05.018","article-title":"Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database","volume":"135","author":"Castaldo","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101100","article-title":"Real-world treatment patterns and burden-of-disease of sub-optimally controlled hereditary angioedema","volume":"18","author":"Farkas","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2026.101474_bib6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/jcm10092023","article-title":"The genetics of hereditary angioedema: a review","volume":"10","author":"Santacroce","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.waojou.2026.101474_bib7","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s13555-021-00593-x","article-title":"Recognition and management of hereditary angioedema: best practices for dermatologists","volume":"11","author":"Manning","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.waojou.2026.101474_bib8","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jaip.2023.01.023","article-title":"Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns","volume":"11","author":"Riedl","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101474_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","article-title":"Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment","volume":"68","author":"Zuraw","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2023.09.039","article-title":"Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: a focus on the Asia-Pacific region","volume":"153","author":"Honda","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/ced\/llad428","article-title":"Delay in diagnosis is the most important proximate reason for mortality in hereditary angio-oedema: our experience at Chandigarh, India","volume":"49","author":"Kumar Jindal","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.waojou.2026.101474_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100758","article-title":"A narrative review of recent literature of the quality of life in hereditary angioedema patients","volume":"16","author":"Chong-Neto","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2026.101474_bib13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13023-025-03539-0","article-title":"The adolescent experience of hereditary angioedema: a qualitative study of disease burden and treatment experience","volume":"20","author":"Broderick","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.waojou.2026.101474_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib16","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2026.101474_bib17","article-title":"The current situation of hereditary angioedema patients in Germany: results of an online survey","volume":"10","author":"Magerl","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.waojou.2026.101474_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2500\/aap.2024.45.240021","article-title":"Physician- and patient-reported outcomes by hereditary angioedema type: data from a real-world study","volume":"45","author":"Anderson","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.waojou.2026.101474_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1710-1492-6-23","article-title":"HAE therapies: past present and future","volume":"6","author":"Zuraw","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0091-6749(89)90082-1","article-title":"Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency","volume":"83","author":"Bork","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib21","series-title":"Package insert. Lexington, MA: Takeda Pharmaceuticals U.S.A. Inc","year":"2023"},{"key":"10.1016\/j.waojou.2026.101474_bib22","series-title":"Package insert. King of Prussia, PA: CSL Behring, LLC","year":"2025"},{"key":"10.1016\/j.waojou.2026.101474_bib23","series-title":"Package insert. Durham, NC: Biocryst Pharmaceuticals Inc","year":"2024"},{"key":"10.1016\/j.waojou.2026.101474_bib24","series-title":"Package insert. Carlsbad, CA: Ionis Pharmaceuticals, Inc","year":"2025"},{"key":"10.1016\/j.waojou.2026.101474_bib25","series-title":"Package insert. King of Prussia, PA: CSL Behring, LLC","year":"2022"},{"key":"10.1016\/j.waojou.2026.101474_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101474_bib27","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.jaip.2025.06.018","article-title":"Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis","volume":"13","author":"Riedl","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101474_bib28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.anai.2023.11.016","article-title":"Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat","volume":"132","author":"Riedl","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100841","article-title":"Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: a subset analysis of the APeX-S trial","volume":"16","author":"Peter","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2026.101474_bib30","series-title":"Package insert. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc","year":"2022"},{"key":"10.1016\/j.waojou.2026.101474_bib31","series-title":"Full product information. BioCryst Ireland Limited","year":"2021"},{"key":"10.1016\/j.waojou.2026.101474_bib32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40265-025-02180-2","article-title":"Garadacimab: first approval","volume":"85","author":"Fung","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.waojou.2026.101474_bib33","series-title":"Product information. Broadmeadows, VIC, Australia: CSL Behring (Australia) Pty Ltd","year":"2025"},{"key":"10.1016\/j.waojou.2026.101474_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1576235","article-title":"Real-world evidence of the effectiveness and utilization of subcutaneous C1INH long-term prophylaxis in patients with HAE in Spain and Germany","volume":"16","author":"Maurer","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib35","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1939-4551-4-S2-S9","article-title":"Hereditary angioedema caused by C1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies","volume":"4","author":"Gower","year":"2011","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2026.101474_bib36","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1007\/s12325-025-03382-6","article-title":"Therapeutic advances in hereditary angioedema: a focus on present and future options","volume":"42","author":"Uminski","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.waojou.2026.101474_bib37","first-page":"2011","article-title":"Corrigendum: breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research","volume":"8","author":"Nicola","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.waojou.2026.101474_bib38","series-title":"Berinert 2000 IU\/3000 IU Powder and Solvent for Solution for Injection (Subcutaneous Use): Summary of Product Characteristics","year":"2025"},{"key":"10.1016\/j.waojou.2026.101474_bib39","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.waojou.2026.101474_bib40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.waojou.2026.101474_bib41","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/j.1537-2995.2012.03590.x","article-title":"Pathogen safety of human C1 esterase inhibitor concentrate","volume":"52","author":"Groner","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.waojou.2026.101474_bib42","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.waojou.2026.101474_bib43","series-title":"Takeda Announces Approval of TAKHZYRO\u00ae (Lanadelumab) Subcutaneous Injection in China for the Treatment of Hereditary Angioedema","year":"2020"},{"key":"10.1016\/j.waojou.2026.101474_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s13223-025-00999-8","article-title":"The International\/Canadian hereditary angioedema guideline","volume":"22","author":"Betschel","year":"2026","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib46","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2026.101474_bib47","unstructured":"Ministry of Health Israel. Andembry\u00ae (garadacimab 167 mg\/mL) solution for injection. The Israeli Drug Registry. Available from: https:\/\/israeldrugs.health.gov.il\/."},{"key":"10.1016\/j.waojou.2026.101474_bib48","series-title":"Full product information. Otsuka Pharmaceutical Netherlands B.V","year":"2026"},{"key":"10.1016\/j.waojou.2026.101474_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.waojou.2026.101474_bib50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.anai.2015.01.003","article-title":"Critical appraisal of androgen use in hereditary angioedema: a systematic review","volume":"114","author":"Riedl","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/JAA.S284029","article-title":"Optimal management of hereditary angioedema: shared decision-making","volume":"14","author":"Banerji","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.waojou.2026.101474_bib52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2500\/aap.2024.45.230080","article-title":"An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy","volume":"45","author":"Lumry","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.waojou.2026.101474_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12016-024-09006-1","article-title":"Hereditary angioedema attacks in patients receiving long-term prophylaxis: a systematic review","volume":"67","author":"Longhurst","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib54","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/cts.12806","article-title":"Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema","volume":"13","author":"Wang","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.waojou.2026.101474_bib55","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.clinthera.2008.12.021","article-title":"Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema","volume":"30","author":"Birjmohun","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.waojou.2026.101474_bib56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13223-020-0409-3","article-title":"Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial","volume":"16","author":"Levy","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12243","article-title":"Current challenges and future opportunities in patient-focused management of hereditary angioedema: a narrative review","volume":"13","author":"Grumach","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.waojou.2026.101474_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18176\/jiaci.0037","article-title":"Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency","volume":"26","author":"Gonzalez-Quevedo","year":"2016","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The International\/Canadian Hereditary Angioedema Guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","article-title":"Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients","volume":"100","author":"Bork","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/whe.16.6","article-title":"Managing the female patient with hereditary angioedema","volume":"12","author":"Banerji","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.waojou.2026.101474_bib62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40271-025-00798-8","article-title":"Patient preferences for long-term prophylactic treatment in hereditary angioedema: a discreet-choice experiment","volume":"19","author":"Villa","year":"2026","journal-title":"Patient"},{"key":"10.1016\/j.waojou.2026.101474_bib63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","article-title":"Hereditary angioedema patients would prefer newer-generation oral prophylaxis","volume":"10","author":"Geba","year":"2021","journal-title":"J Drug Assess"},{"key":"10.1016\/j.waojou.2026.101474_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000546987","article-title":"Long-term real-world outcomes in patients with hereditary angioedema receiving lanadelumab for 3 or more years","volume":"187","author":"Lumry","year":"2026","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fmed.2018.00022","article-title":"Hereditary angioedema: the economics of treatment of an orphan disease","volume":"5","author":"Lumry","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.waojou.2026.101474_bib66","first-page":"s308","article-title":"Economic burden limiting proper healthcare delivery, management, and improvement of patient outcomes","volume":"24","author":"Cardarelli","year":"2018","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.waojou.2026.101474_bib67","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.anai.2018.07.025","article-title":"Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency","volume":"121","author":"Craig","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-021-08854-5","article-title":"Mitigating disparity in health-care resources between countries for management of hereditary angioedema","volume":"61","author":"Jindal","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.anai.2021.09.026","article-title":"Optimization of care for patients with hereditary angioedema living in rural areas","volume":"128","author":"Riedl","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12035","article-title":"Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study","volume":"11","author":"Farkas","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.waojou.2026.101474_bib71","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jaip.2016.03.024","article-title":"Tolerability and effectiveness of 17-\u03b1-alkylated androgen therapy for hereditary angioedema: a re-examination","volume":"4","author":"Zuraw","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101474_bib72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaip.2025.10.027","article-title":"Transient hepatitis as a novel withdrawal phenomenon after danazol discontinuation in hereditary angioedema","volume":"14","author":"de Lange","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101474_bib73","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13223-021-00603-9","article-title":"Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema","volume":"17","author":"Gower","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib74","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1111\/all.70294","article-title":"Switching long-term prophylaxis to donidalorsen for hereditary angioedema: 1-year OASISplus results","volume":"81","author":"Riedl","year":"2026","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2026.101474_bib75","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/all.15948","article-title":"A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema","volume":"79","author":"Petersen","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2026.101474_bib76","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13023-024-03251-5","article-title":"Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series","volume":"19","author":"Hoarau","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.waojou.2026.101474_bib77","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13223-021-00644-0","article-title":"Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series","volume":"18","author":"Maurer","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101474_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.949387","article-title":"Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): a case series","volume":"3","author":"Andarawewa","year":"2022","journal-title":"Front Allergy"},{"key":"10.1016\/j.waojou.2026.101474_bib79","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2500\/aap.2021.42.200106","article-title":"Androgen use in hereditary angioedema: a critical appraisal and approaches to transitioning from androgens to other therapies","volume":"42","author":"Johnston","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.waojou.2026.101474_bib80","series-title":"StatPearls. Treasure Island, FL","article-title":"Pharmacokinetics","author":"Grogan","year":"2025"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455126003078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455126003078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T20:15:17Z","timestamp":1795205717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455126003078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1939455126003078"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2026.101474","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2026.101474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"101474"}}